仙乐健康(300791) - 2025 Q3 - 季度财报
SIRIOSIRIO(SZ:300791)2025-10-28 08:05

Financial Performance - The company's revenue for Q3 2025 reached ¥1,249,554,970.73, representing an 18.11% increase compared to the same period last year[5]. - Net profit attributable to shareholders was ¥99,150,153.03, up 16.20% year-on-year[5]. - The net profit excluding non-recurring gains and losses was ¥84,957,690.14, reflecting a 3.75% increase from the previous year[5]. - The basic earnings per share for the period was ¥0.4227, an increase of 16.25% compared to the same period last year[5]. - Total revenue for the current period reached ¥3,291,173,866.65, an increase of 7.96% compared to ¥3,048,456,382.86 in the previous period[38]. - The net profit for the current period is 221,833,210.02, an increase from 212,725,237.99 in the previous period, reflecting a growth of approximately 5.2%[40]. - The total comprehensive income for the current period is 250,123,513.03, compared to 203,533,929.20 in the previous period, indicating an increase of about 22.8%[40]. - The operating profit for the current period is 260,798,947.13, slightly up from 246,930,167.25 in the previous period, showing a growth of around 5.6%[40]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,877,959,247.31, a 7.14% increase from the end of the previous year[5]. - Total assets amounted to ¥5,877,959,247.31, an increase from ¥5,486,023,079.85, reflecting a growth of 7.13%[37]. - Total liabilities rose to ¥3,128,278,627.72, compared to ¥2,844,825,104.64 in the previous period, marking an increase of 9.96%[37]. - The company's equity attributable to shareholders increased to ¥2,654,056,548.87 from ¥2,505,833,682.05, a growth of 5.91%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥411,096,753.33, showing a significant increase of 45.50%[5]. - Cash flow from operating activities generated a net amount of 411,096,753.33, compared to 282,534,948.04 in the previous period, representing an increase of approximately 45.5%[41]. - The net cash flow from investing activities was negative at ¥294,337,407.24, a 136.64% increase in outflows compared to the previous year, mainly due to increased payments for long-term asset acquisitions[9]. - The net cash flow from investing activities is -294,337,407.24, worsening from -124,381,409.85 in the previous period, indicating a decline in investment cash flow[42]. - The net cash flow from financing activities is -214,036,504.12, compared to -125,820,210.74 in the previous period, showing a decrease in financing cash flow[42]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,761[11]. - Guangdong Guanghui Investment Co., Ltd. holds 42.76% of shares, totaling 131,414,400 shares[11]. - Lin Peiqing and Chen Qiong, as actual controllers, hold 9.12% and 5.56% of shares respectively, totaling 28,035,072 and 17,083,872 shares[11]. - The total number of restricted shares at the beginning of the period was 41,496,504, with 10,420,123 shares added during the period[15]. - The number of restricted shares held by Lin Peiqing increased to 21,026,304 after adding 4,852,224 shares[15]. - The company has a total of 50,794,063 restricted shares at the end of the period[15]. - The number of shares held by the top ten unrestricted shareholders includes 131,414,400 shares from Guangdong Guanghui Investment Co., Ltd.[12]. - The company has no changes in the top ten shareholders participating in margin trading[13]. - The company has no preferred shareholders or changes in preferred shareholders during the reporting period[14]. Stock Incentive and Repurchase - The company’s stock incentive plan includes 1,593,800 shares added to the restricted stock plan for 2025[16]. - The company completed the repurchase and cancellation of restricted stocks that were granted but not yet released from restrictions, amounting to 30% of the granted shares due to unmet release conditions[17]. - Company executives plan to reduce their holdings, with Vice General Manager Yao Zhuangmin intending to sell up to 2,019,489 shares (approximately 0.66% of total shares) and Director Yang Rui planning to sell up to 2,481,491 shares (approximately 0.81% of total shares)[18]. - Vice General Manager Zheng Liqun purchased 140,000 shares, representing 0.05% of the total share capital after excluding repurchased shares[19]. - Shareholder Yao Zhuangmin released 1,885,000 shares from pledge, leaving 715,000 shares still pledged[20]. - The company's registered capital increased from CNY 235,872,880 to CNY 307,318,960, and total shares increased from 235,872,880 to 307,318,960 due to the implementation of the 2025 restricted stock incentive plan and other adjustments[22]. - The company adjusted the repurchase price of the 2023 restricted stock incentive plan from CNY 9.78 per share to CNY 7.52 per share, and the number of shares involved was increased from 841,750 to 1,094,275[25]. Investments and Business Strategy - The company is investing up to USD 40 million to establish a production base in Thailand, with land acquisition costs approximately THB 489,285,000 (around CNY 108,626,162.85)[30]. - The company is seeking investment, divestment, or sale opportunities for its subsidiary Best Formulations PC LLC to optimize its U.S. business structure[31]. - The company approved the grant of 364,000 shares of restricted stock at a price of CNY 9.71 per share to 23 eligible participants under the 2025 restricted stock incentive plan[33]. - The company terminated the "Long-term Employee Stock Ownership Plan" due to significant changes in the market environment and the company's specific situation, which made the plan no longer suitable for current conditions[34]. Operating Costs and Expenses - Total operating costs increased to ¥3,046,438,602.78, up 8.26% from ¥2,813,726,698.28 in the previous period[38]. - Research and development expenses for the current period were ¥100,513,939.25, slightly up from ¥98,626,917.14 in the previous period[38]. - The company's cash and cash equivalents decreased to ¥541,548,259.12 from ¥636,030,607.22, a decline of 14.89%[35]. - Accounts receivable increased to ¥829,378,623.81, up 22.83% from ¥675,014,555.79 in the previous period[35]. - The company recorded a tax expense of 33,122,608.71 for the current period, compared to 29,224,869.86 in the previous period, which is an increase of approximately 13.3%[40].